Oregon Department of Corrections
Approved Formulary
Search by name
Browse alphabetically
Select...
NUM
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Hazardous Drugs
In-Cell HD
Earned In-Cell
Formulary Duration Restrictions
Therapeutic Substitutions
Webpage Links
Add Formweb to your mobile device
Android
iOS
Home
QuickStart
Admin
February P&T meeting minutes have been posted.
Oregon Department of Corrections
Approved Formulary
Search by name
Additional search options
Search by class
Browse alphabetically
Select...
NUM
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Hazardous Drugs
In-Cell HD
Earned In-Cell
Formulary Duration Restrictions
Therapeutic Substitutions
Webpage Links
Search results for:
metroNIDAZOLE
metroNIDAZOLE
Formulary Duration Restrictions
Limited to 6 weeks without TLC approval.
Cell Status
Approved
Brand names:
Flagyl
Form
Strength
TABLET, ORAL
250 mg
Additional Information:
FEBRUARY 2024 P&T MINUTES
JANUARY 2022 P&T MINUTES
Last updated:
Mar. 11, 2024
Black Box Warning:
Carcinogenicity
FDA Drug Safety:
Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research for Flagyl (metronidazole) 500 mg I.V. injection RTU (in plastic container)
UpToDate
Micromedex
Pharmacist's Letter
FDA DailyMed Package Insert
WebMD Pill Identifier
FEBRUARY 2024 P&T MINUTES
JANUARY 2022 P&T MINUTES